Atlanta 2/20/2013 5:58:34 AM
Miraculins Inc. (Stock Symbol: CVE: CA:MOM) is now on LinkMyStock.com
Miraculins Inc. has joined LinkMyStock.com. Now Stock Brokers, Brokerage Firms and Investors/Shareholders from around the world who follow Miraculins Inc. can link directly to Miraculins Inc. Link My Stock Hub. Brokers and Brokerage Firms that link to Miraculins Inc. typically are familiar with the company and can facilitate transactions in Miraculins Inc. security. Investors linking to Miraculins Inc. usually are either existing shareholders looking to stay informed when Miraculins Inc. posts new information or people that are simply interested in Miraculins Inc. that are not yet or may never become shareholders.
LinkMyStock is a premier financial networking platform designed specifically for public companies, brokerage firms, brokers and investors. LinkMyStock.com provides a network that consists of brokers, brokerage firms and investors that can link directly to the companies that they follow. With brokers from around the world having the ability to select companies to link to that are members of Link My Stock this provides investors with the ability to locate brokers and contact them to find out more information about a company they are interested in learning more about.
LinkMyStock.com provides every member with their own hub where they post content. Content sections include; press releases, blogs, pictures, videos, Right Now status updates, events, jobs and more in order to attract more visitors and increase the number of search results along with improving indexing.
To link to the Miraculins Inc.'s Link My Stock Hub sign into your Link My Stock Hub or Join Link My Stock today.
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu® technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is partnered with Alere Inc., one of the world's largest diagnostic companies.